Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,971 shares of the biopharmaceutical company's stock, valued at approximately $445,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. IFM Investors Pty Ltd lifted its position in Gilead Sciences by 8.7% during the first quarter. IFM Investors Pty Ltd now owns 270,605 shares of the biopharmaceutical company's stock valued at $30,321,000 after purchasing an additional 21,655 shares during the last quarter. GF Fund Management CO. LTD. lifted its position in Gilead Sciences by 3.0% during the first quarter. GF Fund Management CO. LTD. now owns 292,840 shares of the biopharmaceutical company's stock valued at $32,813,000 after purchasing an additional 8,484 shares during the last quarter. Calamos Advisors LLC lifted its position in Gilead Sciences by 1.1% during the first quarter. Calamos Advisors LLC now owns 234,785 shares of the biopharmaceutical company's stock valued at $26,308,000 after purchasing an additional 2,514 shares during the last quarter. Davidson Trust Co. bought a new position in shares of Gilead Sciences during the 1st quarter valued at approximately $203,000. Finally, Checchi Capital Advisers LLC increased its position in shares of Gilead Sciences by 5.1% during the 1st quarter. Checchi Capital Advisers LLC now owns 11,109 shares of the biopharmaceutical company's stock valued at $1,245,000 after purchasing an additional 544 shares during the last quarter. Institutional investors own 83.67% of the company's stock.
Gilead Sciences Stock Performance
GILD stock traded down $0.69 during trading on Tuesday, reaching $111.09. The company had a trading volume of 3,544,118 shares, compared to its average volume of 7,691,231. The firm has a 50-day simple moving average of $107.12 and a 200-day simple moving average of $104.25. The company has a market cap of $138.19 billion, a price-to-earnings ratio of 23.39, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a twelve month low of $66.34 and a twelve month high of $119.96.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. Gilead Sciences's revenue for the quarter was down .3% on a year-over-year basis. During the same period last year, the business earned ($1.32) EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.84%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on GILD shares. Morgan Stanley boosted their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Oppenheimer decreased their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Finally, Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $110.55.
Read Our Latest Stock Report on Gilead Sciences
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $330,510.00. Following the completion of the sale, the insider directly owned 120,168 shares in the company, valued at approximately $13,238,908.56. The trade was a 2.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 30th. The shares were sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the transaction, the chief executive officer directly owned 615,725 shares of the company's stock, valued at approximately $68,006,826.25. This trade represents a 1.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,500 shares of company stock worth $6,340,745. Company insiders own 0.27% of the company's stock.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
